Eleventh Amendment to March 2022 Convertible Note Transaction Documents

Contract Categories: Business Finance - Note Agreements
EX-10.41 13 ex10-41.htm

 

Exhibit 10.41

 

Eleventh Amendment to Transaction Documents

 

This Eleventh Amendment to the Transaction (this “Amendment”) is effective as of April 5, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as amended, entered between the Parties (the “Securities Purchase Agreement”)

 

Recitals

 

WHEREAS, pursuant to the Transaction Documents, Puritan Partners purchased a 12.5% Original Issue Discount Senior Secured Note in the principal amount of $1,142,857.14 due March 2, 2023 (as amended, the “Note”) and was issued a common stock purchase warrant to purchase 22,857,143 shares of the common stock at $0.0001 exercise price (as amended, the “Warrant”);

 

WHEREAS, Puritan Partners and Company are parties to the Transaction Documents, which were previously amended on August 18, 2022, October 2, 2022, October 14, 2022, November 2, 2022, November 16, 2022, December 16, 2022, January 11, 2023, January 31, 2023, February 17, 2023, and March 16, 2023 and the parties now desire to further amend the respective Transaction Documents in accordance with the terms of this Amendment.

 

NOW, THEREFORE, in consideration of the following and other consideration, the receipt of which is hereby acknowledged, the parties agree as follows:

 

Section (e)(iii) of the Tenth Amendment to Transaction Documents dated March 16, 2023, will be deleted in its entirety and hereby replaced with the following: “April 2, 2023, will be paid in full no later than April 19, 2023”

 

Each of the undersigned has caused this Amendment to be duly executed and delivered as of the date first written above and will become effective as of the Effective Date.

 

CURATIVE BIOTECHNOLOGY, INC.  
     
By: /s/ Richard Garr  
Name: Richard Garr  
Title: Chief Executive Officer